| Model Number |
9004 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Reocclusion (1985)
|
| Date of Event |
07/23/2018
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
The sample was not returned from the user facility; therefore, a device evaluation is unable to be performed.A lot history review revealed there is no similar reocclusion complaints associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual sample was not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided with all relevant information.
|
| |
|
Event or Problem Description
|
|
It was reported through a post market clinical study that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the left popliteal artery.Approximately 4 months after the index procedure, the patient¿s left popliteal artery was reportedly reoccluded.A revascularization was performed and the health care professional (hcp) deemed it was successful.The investigator assessed that the event was not related to the study device or to the procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.
|
| |
|
Event or Problem Description
|
|
It was reported through a post market clinical study that during the index procedure, a lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter was used to treat the target lesion located in the left popliteal artery.Approximately 4 months after the index procedure, the patient¿s left popliteal artery was reportedly reoccluded via duplex ultrasound (dus) imaging.A revascularization involving a cutting/scoring balloon and placement of a bare metal stent was performed.The health care professional (hcp) deemed the revascularization was successful.The investigator assessed that the event was not related to the study device or to the procedure.The sample was discarded by the user facility and is not available for evaluation.No adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
The event description had the following information added ".Via duplex ultrasound (dus) imaging.A revascularization involving a cutting/scoring balloon and placement of a bare metal stent was performed.The health care professional (hcp) deemed the revascularization was successful." the relevant tests and lab data had the following information added "on (b)(6) 2018, dus imaging indicated target lesion was 90% reoccluded.The patients had a resting abi = 0.64 in left leg and a rutherford class assessment of v in left leg.A reintervention involving a cutting/scoring balloon and placement of a bare metal stent was performed." the complainant occupation - other was updated with "cardiovascular internal medicine" corrected data: the mdr contact person and email address were changed to (b)(6).The mdr contact phone number was changed to (b)(6).H3 analysis: the sample was not returned from the user facility; therefore, a device evaluation is unable to be performed.A lot history review revealed there is no similar reocclusion complaints associated with this lot.A review of the device history record (dhr) indicates the lot was manufactured to specification.Conclusion: the actual sample was not returned for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided with all relevant information.H11:section a through f - the information provided by bd represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bd.
|
| |
|
Search Alerts/Recalls
|